Selected stock price target news of the day - March 26th, 2025

By: Matthew Otto

Atossa Therapeutics Reports 2024 Financial Results and Advances Breast Cancer Program

Atossa Therapeutics reported $71.1 million in cash and cash equivalents as of December 31, 2024, with no outstanding debt. Continues to advance its lead candidate, (Z)-endoxifen, focusing on metastatic breast cancer. This affects approximately 168,000 patients in the U.S. alone.

Prior clinical trials demonstrated (Z)-endoxifen’s promising efficacy and safety profile, with tumor suppression rates exceeding 85% across multiple dosing levels. Atossa remains engaged with the U.S. Food and Drug Administration (FDA) for additional indications, including breast cancer prevention and neoadjuvant therapy. More than 300,000 new cases of invasive breast cancer are diagnosed annually in the U.S., and an estimated 43,000 patients die from the disease each year.

During the San Antonio Breast Cancer Symposium (SABCS), Atossa presented pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial, which involved premenopausal women with ER+/HER2- breast cancer. The study showed that (Z)-endoxifen achieved target tissue concentrations without significant Grade 3 or 4 toxicities. A revised study protocol will now compare a 40 mg daily dose plus ovarian function suppression (OFS) to exemestane plus OFS.

Additionally, Phase 2 KARISMA-Endoxifen study results indicated a 1 mg dose reduced mammographic breast density (MBD) by 17.3 percentage points (p<0.01), while a 2 mg dose achieved a 23.5 percentage-point reduction (p<0.01), outperforming the placebo group (0.27 percentage points). Nearly 40 million women undergo mammograms annually in the U.S., and about 50% of them have dense breast tissue—raising their risk of breast cancer.

Analyst Reiterates Rating Amid Program Advances

HC Wainwright & Co. analyst Emily Bodnar reiterated with a Buy rating and a $7 price target.

Which Analyst has the best track record to show on ATOS?

Analyst Edward Woo (ASCENDIANT) currently has the highest performing score on ATOS with 2/2 (100%) price target fulfillment ratio. His price targets carry an average of $4.13 (106.72%) potential upside. Atossa Therapeutics stock price reaches these price targets on average within 51 days.

Lightspeed Revises Fiscal 2025 Revenue Outlook Amid Economic Challenges

Lightspeed Commerce has updated its financial outlook for the fiscal year ending March 31, 2025, reflecting recent macroeconomic challenges. Since reporting its third-quarter results on February 6, 2025, Lightspeed has observed a decline in consumer discretionary spending due to heightened inflation, increased job insecurity, and weakening consumer confidence. This has resulted in lower same-store sales in February and March, along with a slowdown in small business formation.

Consequently, Lightspeed now expects fiscal 2025 revenue to grow approximately 18% year over year, down from the previously projected 20%. It continues to anticipate an adjusted EBITDA of over $53 million, despite pressures on transaction-based and, to a lesser extent, subscription revenue.

In response to these headwinds, Lightspeed remains committed to profitable growth and cost management while reinforcing its core strategy of providing integrated commerce solutions. Lightspeed expects approximately 7-8% subscription revenue growth in the fourth quarter and is actively driving the adoption of its unified point-of-sale (POS) and payments platform.

Analysts Lower Price Targets as Revenue Outlook is Revised

RBC Capital analyst Daniel Perlin yesterday maintained an Outperform rating while lowering the price target from $20 to $15.
Scotiabank analyst Kevin Krishnaratne yesterday kept a Sector Outperform rating but reduced the price target from $19 to $17.

Which Analyst has the best track record to show on LSPD?

Analyst Timothy Chiodo (UBS) currently has the highest performing score on LSPD with 5/6 (83.33%) price target fulfillment ratio. Her price targets carry an average of $1.38 (10.52%) potential upside. Lightspeed Commerce stock price reaches these price targets on average within 47 days.

Lucid Diagnostics Reports EsoGuard Testing Volume and Financial Growth in Q4 2024

Lucid Diagnostics reported growth in the fourth quarter of 2024, processing a record 4,042 EsoGuard tests—a 45% sequential increase and an 84% rise year-over-year. EsoGuard-related revenue reached $1.2 million in Q4, contributing to a full-year revenue total of $4.3 million, up from $2.4 million in 2023. However, Q4 revenue fell short of analyst expectations of $1.43 million.

Despite revenue growth, Lucid reported a GAAP net loss of $11.5 million in Q4, with operating expenses reaching $13.6 million, including $1.2 million in stock-based compensation. Q4 EPS came in at ($0.19), missing analyst estimates of ($0.17) by $0.02. Also completed $32.8 million in financings, bolstering its cash position to approximately $36.9 million at the start of 2025.

Analyst Reiterates Ratings as EsoGuard Testing Grows in Q4 2024

Cantor Fitzgerald analyst Ross Osborn reiterated with an Overweight rating and a $2 price target.